ASLAN Pharmaceuticals Limited Share Price
Equities
ASLN
US04522R2004
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4153 USD | -7.30% | -18.89% | -20.46% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 307M 9.41M 753M |
---|---|---|---|---|---|
Net income 2024 * | -2.14B -65.53M -5.24B | Net income 2025 * | -1.82B -55.83M -4.47B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.11
x | P/E ratio 2025 * |
-0.17
x | Employees | 35 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
1 day | -7.30% | ||
1 week | -18.89% | ||
Current month | -32.49% | ||
1 month | -34.60% | ||
3 months | -30.67% | ||
6 months | -65.10% | ||
Current year | -20.46% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 51 | 31/12/09 | |
Director of Finance/CFO | 45 | 31/10/10 | |
Chief Tech/Sci/R&D Officer | - | 14/03/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 29/10/18 |
Chairman | 64 | 31/03/16 | |
Founder | 51 | 31/12/09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.4153 | -7.30% | 645,378 |
25/04/24 | 0.448 | -4.68% | 319,651 |
24/04/24 | 0.47 | +0.21% | 1,035,372 |
23/04/24 | 0.469 | +3.08% | 1,517,006 |
22/04/24 | 0.455 | -11.13% | 11,382,802 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.46% | 9.4M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ASLN Stock